CTOs on the Move

Quality of Life Health Services

www.qolhs.org

 
Quality of Life Health Services is a Gadsden, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.qolhs.org
  • 1411 Piedmont Cutoff
    Gadsden, AL USA 35903
  • Phone: 888.490.0131

Executives

Name Title Contact Details

Similar Companies

Gerigene Medical Corporation

Gerigene Medical Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biocodex

Biocodex is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Summa Health

Summa Health is one of the largest integrated delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and multiple foundations, Summa is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa also is a founding partner of the BioInnovation Institute in Akron. For more information, visit www.summahealth.org. Summa Health is an Affirmative Action employer that promotes Equal Employment Opportunity and Diversity for all individuals. Women, veterans, members of minority groups, and individuals with disabilities are encouraged to apply.

Rogers Group

Headquartered in Nashville, Tennessee, Rogers Group Inc. provides crushed stone, sand and gravel, asphalt and highway construction to the southeastern United States. In 2009, the company was listed as the ninth largest aggregates producer in the nation...

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.